Germany’s Medical Cannabis Market Is Becoming a Global Supply Opportunity

LOS ANGELES- Germany’s medical Cannabis market offers North American producers an opportunity that exists today: supplying prescription products through an established pharmaceutical channel. Its significance lies in the combination of rising imports, regulated distribution and buyers able to source internationally.

Understanding that opportunity requires looking beyond legalization headlines. The market is shaped by prescribing, pharmacy access, product specifications and the ability to deliver consistent batches at a competitive price.

A medical market with its own rules

Germany’s 2024 reforms created distinct frameworks for adult home cultivation, noncommercial cultivation associations and medical Cannabis. These are separate routes to access, with different commercial implications. The medical system is the relevant established channel for international suppliers. [1]

Under the Medical Cannabis Act, physicians prescribe and pharmacies dispense against a prescription. Businesses undertaking activities such as commercial importation and distribution require the applicable permissions. [2]

Consequently, the route to a patient runs through several professional buyers and gatekeepers. Cultivators sell into a supply chain whose purchasing decisions depend on quality, documentation, availability and price. A popular recreational cultivar does not automatically become a suitable medical import.

Imports reveal the size of the opportunity

Germany imported approximately 201,094 kilograms of Cannabis in 2025, compared with roughly 72,850 kilograms in 2024, according to BfArM figures reported by StratCann. Canada supplied 93,006 kilograms, approximately 46% of the total, while Portugal supplied 55,164 kilograms. [3]

These are import volumes, rather than pharmacy sales or patient consumption. Inventory, onward trade and subsequent reporting revisions affect their interpretation. They establish the scale of cross-border supply without proving that every imported gram has found a patient.

Canada’s position shows that North American participation is already substantial. Portugal’s role also illustrates why the country exporting a finished shipment and the original cultivation location should not automatically be treated as the same thing.

An expanding market still creates competition. Importers can compare suppliers across jurisdictions, while local production provides another source of supply. Exporters therefore need to identify a specific customer requirement, rather than assume that Germany will absorb any available harvest.

What German buyers need

Flower and extracts require different specifications and processing arrangements. Even within flower, buyers may seek different cannabinoid profiles, cultivars, batch sizes and price points.

Consistency has commercial value. A buyer needs confidence that the next shipment will meet the same agreed specification, arrive with complete records and support continuity of treatment. A discounted batch is less attractive if the product cannot be reordered reliably.

How North America can serve the market

Canada offers an established legal route for qualifying medical or scientific exports. Health Canada requires a permit for each shipment; holding a domestic Cannabis licence does not authorize unrestricted overseas sales. [5]

European pharmaceutical quality requirements apply alongside those export controls. Good manufacturing practice addresses manufacturing quality, while good distribution practice protects product integrity during storage and distribution. The obligations depend on the product and the activities performed at each site. [6]

In practice, a transaction requires more than a purchase order. The parties need agreed specifications, supplier qualification, testing responsibilities, batch documentation, import arrangements and clear acceptance terms. A failure at one stage can delay the entire transaction.

This creates a market for processors and intermediaries that coordinate the steps between cultivation and pharmaceutical distribution. Producers can retain their cultivation focus while using specialist partners for activities they are not equipped or authorized to perform.

A case in point

Alberta-based High Ground Medica illustrates that model. The company reports an active German export relationship and describes a platform combining Canadian sourcing, processing oversight and export coordination. Its proposed satellite processing and North American sublicensing strategy would extend participation to approved producers. These remain company-described capabilities and plans; individual sites and shipments still need the relevant approvals. [4]

DEA: Drug Enforcement Administration

The economics extend beyond the wholesale spread

The gap between a producer’s selling price and a German pharmacy’s retail price is not an exporter’s margin. Different businesses perform different services along the route, and each carries costs and risks.

Processing, testing, packaging, freight, insurance and financing must be paid before a transaction’s return can be assessed. Inventory rejection, delayed acceptance and slow collections can turn an attractive quoted spread into a disappointing cash result.

Working capital deserves particular attention. A supplier may pay for product and preparation well before receiving payment from its European customer. Increasing volume can therefore increase financing needs even when sales appear healthy.

Commercial discipline begins with the buyer. Clear specifications, realistic delivery schedules and enforceable acceptance and payment terms matter as much as cultivation cost.

Access policy is another variable. Changes in prescribing or dispensing rules can affect how easily patients obtain treatment and how quickly inventory moves. An export strategy should withstand slower growth, changing demand and lower selling prices.

Where lasting value is likely to develop

Germany’s opportunity is broader than moving inexpensive flower across the Atlantic. It includes product development, pharmaceutical processing, quality services, distribution and the financing of dependable supply.

For Canadian producers, the immediate task is to establish repeat business with authorized buyers. For U.S. producers, any future route requires the applicable federal permissions alongside destination-market compliance. Demand in Germany cannot substitute for authorization in the country of origin.

The EU should also be understood as a collection of national medical markets. Pharmaceutical standards provide common reference points, but Germany’s rules on prescribing and patient access do not automatically apply elsewhere.

The most useful measures of progress are accepted shipments, repeat orders, consistent supply and collected cash. Headline import growth identifies an opportunity; those operating results establish whether a supplier has built a business.

Germany has become a significant destination for international medical Cannabis. Its next phase will reward suppliers that understand the healthcare channel as thoroughly as they understand the crop.

Sources

[1] German Federal Ministry of Health, Cannabis Act overview: https://www.bundesgesundheitsministerium.de/service/gesetze-und-verordnungen/detail/cannabisgesetz

[2] Medical Cannabis Act, particularly sections 3, 4 and 12: https://www.gesetze-im-internet.de/medcang/BJNR06D0C0024.html

[3] StratCann, 3 March 2026, reporting BfArM import data; figures may be revised and are not patient sales: https://stratcann.com/news/canada-continued-to-supply-the-bulk-of-german-medical-cannabis-imports-in-2025/

[4] High Ground Medica, company description of its international distribution model: https://hgmedica.ca/intl-distribution

[5] Health Canada, Importing and exporting cannabis: https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/industry-licensees-applicants/manage-licence-cultivation-processing-sale-medical-purposes/apply-import-export.html

[6] European Commission, Good Manufacturing and Distribution Practices: https://health.ec.europa.eu/medicinal-products/good-manufacturing-and-distribution-practices_en

Market analysis prepared on 22 October 2026. Company examples are illustrative; approvals and performance have not been independently audited.

HCN thanks author Jason Hart of Archer Loch Capital, specializing in stock-backed and asset-backed financing. Contact: https://www.linkedin.com/in/jason-hart-716a977 | [email protected] | +1 954-594-2155 | https://archerlochcapital.com/. Disclosure: HGM is an HCN client. © 2026 Highly Capitalized Network. All rights reserved. Republication: contact HCN. This article is provided for general informational purposes only. It does not constitute an offer to sell or a solicitation of an offer to purchase any security or financial instrument. Company plans, projections and proposed financing terms are forward-looking, subject to change and dependent on financing, due diligence, regulatory approvals and definitive agreements. Sponsored content.